Protheragen Launches Specialized Pharmacokinetic Service Platform for Anti-Obesity Therapeutics

United States, September 15, 2026 /MarketersMEDIA/ -- Protheragen, a contract research organization (CRO) focused on preclinical drug development services, has launched a service offering focused on preclinical in vivo and in vitro pharmacokinetic (PK) evaluation of anti-obesity therapeutic drugs. According to the WHO, more than one billion people worldwide are living with obesity, creating an urgent need for safe and effective new therapeutic drugs. The integrated service offering provides biotech and pharma partners with key ADME data to reduce risk and accelerate development of next-generation anti-obesity therapeutics.

Protheragen's anti-obesity therapeutic PK study offering is a specialized service, compared to conventional PK evaluations, that takes into account the fundamental changes that the state of obesity imposes on human physiology (i.e. changes in gastric emptying, metabolic organ perfusion, and metabolic rate). As a result of these changes, the behavior of drugs in the body is also altered, making conventional PK assessments insufficient. The integrated, one-stop research program undertaken by Protheragen is designed to understand drug behavior and address challenges associated with drug fate and elimination.

Protheragen's integrated service offering includes in-depth evaluation of candidate drugs for anti-obesity therapeutics in terms of absorption, distribution, metabolism, and excretion. This includes assessment of absorption and bioavailability, concentration of the drug in different tissues with evaluation of the organ blood flow and binding of the drug with plasma proteins. Protheragen employs high-performance liquid chromatography (HPLC), thin layer chromatography (TLC), capillary electrophoresis (CE), and mass spectrometry (MS) to identify metabolites of drugs and their pathways. The company also constructs validated obesity models—spanning cell-based systems and animal models such as mice, rats, rabbits, and beagles—ensuring PK data is generated in biologically relevant systems.

Beyond PK analysis, Protheragen offers comprehensive services for therapeutic modalities that include small molecules, gene therapies, cell therapies, antibody therapies, tissue engineering, and nanotherapies. Within small molecule therapies, Protheragen performs natural products and compound screens on the melanocortin-4 receptor (MC4R), leptin receptor (LepR), and adiponectin receptor (AdipoR) pathways. For advanced biologics, Protheragen employs gene editing to design tailored gene therapies, uses phage display and hybridoma technologies for antibody design, and evaluates nanotechnology for weight loss. Protheragen can assist partners from target identification to IND-enabling.

The purpose of the Protheragen Pharmacokinetic Study of Anti-Obesity Therapeutics is to characterize the pharmacokinetic profile and exposure-response relationships of drug candidates, determine optimal dosing regimens, and identify potential drug-drug interactions—data that inform subsequent safety, efficacy, and combination therapy design. Protheragen has the experience to perform the studies and provide comprehensive reports to support clients in making informed decisions. As obesity research evolves toward precision medicine, Protheragen remains committed to providing the scientific foundation for safer, more effective therapies.

About Protheragen

Protheragen is a premier CRO dedicated to accelerating drug discovery through innovative preclinical solutions. With state-of-the-art laboratories and expert scientists, the company provides services spanning disease modeling, PK/PD evaluation, safety assessment, and bioanalysis. Protheragen specializes in obesity, oncology, and metabolic disorders, empowering partners to transform discoveries into life-changing medicines.

Contact Info:
Name: Anna White
Email: Send Email
Organization: Protheragen
Website: https://www.obesityscientific.com/

Release ID: 89203368

In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.